A Phase I study of intermittently dosed vorinostat in combination with bortezomib in patients with advanced solid tumors - Wikidata - wikimedia - TriplyDB

A Phase I study of intermittently dosed vorinostat in combination with bortezomib in patients with advanced solid tumors

A Phase I study of intermittently dosed vorinostat in combination with bortezomib in patients with advanced solid tumors

http://www.wikidata.org/entity/Q33410836

about

Preclinical Data on Efficacy of 10 Drug-Radiation Combinations: Evaluations, Concerns, and Recommendations Epigenetic treatment of solid tumours: a review of clinical trials Pancreatic cancer: optimizing treatment options, new, and emerging targeted therapies Trial Watch: Proteasomal inhibitors for anticancer therapy Ritonavir and ixazomib kill bladder cancer cells by causing ubiquitinated protein accumulation.Combination of proteasome and HDAC inhibitor enhances HPV16 E7-specific CD8+ T cell immune response and antitumor effects in a preclinical cervical cancer model Bortezomib alleviates drug-induced liver injury by regulating CYP2E1 gene transcription.Efficacy of bortezomib in sarcomas with high levels of MAP17 (PDZK1IP1).Impact of Histone Deacetylase Inhibitors on microRNA Expression and Cancer Therapy: A Review.Therapeutic applications of histone deacetylase inhibitors in sarcoma.HDAC-4 regulates claudin-2 expression in EGFR-ERK1/2 dependent manner to regulate colonic epithelial cell differentiation.Targeting protein quality control pathways in breast cancer.

P2860

Q26767798-22261708-89BF-4C03-AF3E-2AEB84274D2A Q26773803-C6926311-6493-4F56-8FEC-02CA2B874181 Q26799714-89C25022-02DF-4B00-A722-4E5D2480DCEA Q28082910-D9784A5E-7FA1-480C-993C-49B0F89902AC Q33823282-4DC9059D-A1E2-41C0-946B-3029B73D772A Q34984542-C7372FFF-1E74-4233-AF96-A5BC552F4D17 Q36630651-69928CCD-B932-4D05-9F94-FE7C4B049F53 Q37687113-21E4998B-8BD2-4A25-8892-F9552D09BE76 Q38572855-2F81B4FD-C6E8-48AF-94C1-3DCCDEA505B4 Q39450827-AC64CFAA-B95A-4F66-B75D-F5061E717800 Q45327665-AA80CE40-A688-417F-A320-5835C9E86938 Q46087491-735B9840-6B2B-4F43-922A-E4C9045FD3CB

P2860

A Phase I study of intermittently dosed vorinostat in combination with bortezomib in patients with advanced solid tumors

http://www.wikidata.org/entity/Q33410836

description

2013 nî lūn-bûn

@nan

2013 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

A Phase I study of intermitten ...... nts with advanced solid tumors

@ast

A Phase I study of intermitten ...... nts with advanced solid tumors

@en

type

label

A Phase I study of intermitten ...... nts with advanced solid tumors

@ast

A Phase I study of intermitten ...... nts with advanced solid tumors

@en

prefLabel

A Phase I study of intermitten ...... nts with advanced solid tumors

@ast

A Phase I study of intermitten ...... nts with advanced solid tumors

@en

P1433

Q33410836-98D60339-4312-4E16-A183-2C0A869871ED

P1476

Q33410836-EF8DC0F1-0BD8-4729-AB8D-7C66F0028120

P2093

Q33410836-0CA6EA27-E216-41A4-B340-403A9BF2556E

Q33410836-34ED8AA4-334A-480B-B275-A2AF72870CE7

Q33410836-3C81F692-286B-4606-A1EB-0876225F9476

Q33410836-513BE4BB-F7BB-49AB-97BD-E371DC5D1558

Q33410836-68786B1B-F224-446D-B399-AF95BE68F4E9

Q33410836-6D25BBCC-E8F7-4EAD-B683-F50E667B1D48

Q33410836-74753BE6-2365-4416-9B59-F1BA15349488

Q33410836-8CD7F3C3-9138-4080-A19E-24431FA18EF9

Q33410836-9D0062E0-7AC1-48D5-8D57-CC4E1E2C0B62

Q33410836-AEFC50D8-4E7A-4B1B-8BB4-98EEFCD0AE29

P2860

Q33410836-00C053AF-EDC3-48D0-81E9-AC34821C1011

Q33410836-15110B5F-EB98-499B-AB50-2E8367A2387B

Q33410836-264E6278-AA87-49AC-AC25-ED8B1B08FF7F

Q33410836-279621D6-40AD-4878-AC50-E1BD64FAB04F

Q33410836-2CF8D794-954A-4C7B-9563-9AF0C2C1A6E8

Q33410836-38A244A5-E21F-4CF6-8DEE-FC3E48CB1A5D

Q33410836-3C7EC4D8-A0FD-43AE-A01B-BCB408933A74

Q33410836-4B14E310-34EE-4700-A60D-EFC30A0862ED

Q33410836-679125C3-4204-4DF0-AC92-008535E6FA5E

Q33410836-78FD7CB9-2CD1-40D7-AE64-B9BD3D907014

P2888

Q33410836-13D24DAB-5882-4A45-99FA-727A09C83DD5

P304

Q33410836-5876255F-92BE-4B1F-B3DE-7EC798BA6759

P31

Q33410836-580BD825-05ED-4C52-99E2-D27DA283BF71

P356

Q33410836-733B63DF-F86C-43CA-88A4-6F3590ACB875

P433

Q33410836-E3F58F0B-BD7C-4D92-9B69-531B40DB6EC0

P478

Q33410836-5A3171F2-E9F8-45AF-91C1-6BBB8C3BF595

P50

Q33410836-1E75E69D-D698-4E0A-AFB4-C4D44920D4A3

P577

Q33410836-067E8FCE-BBA3-49E4-9959-477648B9047F

P6179

Q33410836-8B010268-B7D4-4D32-936C-F3D034C611FF

P698

Q33410836-D174BDDB-9AD6-4390-98A4-2F57FE8EEE8A

P932

Q33410836-E734D275-475D-4392-AABA-338F20C8C004

P356

S10637-013-0035-8

P1433

Investigational New Drugs

P1476

A Phase I study of intermitten ...... nts with advanced solid tumors

@en

P2093

Dona Alberti

http://www.w3.org/2001/XMLSchema#string

Dustin A Deming

http://www.w3.org/2001/XMLSchema#string

Howard H Bailey

http://www.w3.org/2001/XMLSchema#string

Igor Espinoza-Delgado

http://www.w3.org/2001/XMLSchema#string

Jacob Ninan

http://www.w3.org/2001/XMLSchema#string

Jens Eickhoff

http://www.w3.org/2001/XMLSchema#string

Jill M Kolesar

http://www.w3.org/2001/XMLSchema#string

Joel M Reid

http://www.w3.org/2001/XMLSchema#string

John Wright

http://www.w3.org/2001/XMLSchema#string

Matthew M Ames

http://www.w3.org/2001/XMLSchema#string

P2860

Histone deacetylase inhibitors: Potential in cancer therapy

The fundamental role of epigenetic events in cancer

Alteration of nucleosome structure as a mechanism of transcriptional regulation

Proteasome inhibition sensitizes non-small cell lung cancer to histone deacetylase inhibitor-induced apoptosis through the generation of reactive oxygen species.

Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies.

Cancer genetics and epigenetics: two sides of the same coin?

Histone deacetylase inhibitors: from chromatin remodeling to experimental cancer therapeutics.

A phase I study of vorinostat in combination with bortezomib in patients with advanced malignancies.

Epigenetic drivers of genetic alterations.

Epigenetics and cancer, 2nd IARC meeting, Lyon, France, 6 and 7 December 2007.

P2888

s10637-013-0035-8

P304

323-329

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10637-013-0035-8

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

32

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-10-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1047247330

http://www.w3.org/2001/XMLSchema#string

P698

24114123

http://www.w3.org/2001/XMLSchema#string

P932

3949160

http://www.w3.org/2001/XMLSchema#string